Bills · HR 1518
IN COMMITTEE· 119TH CONGRESS
House BillHR 1518Medical researchResearch administration and funding
New Era of Preventing End-Stage Kidney Disease Act
INTRO FEB 24· LAST ACTION FEB 24
READING
8MIN
COSPONSORS
56BIPARTISAN
READER REACTIONS0 TOTAL
NO VOTES YET · BE THE FIRST
- Introduced only
LEGISLATIVE PROGRESS
STEP 2 / 8Introduced
In Committee
Reported
Passed House
Passed Senate
Conference
To President
Became Law
WHAT THE BILL DOES
AI-writtenRare kidney diseases can be devastating, often leading to end-stage kidney disease, which requires costly and life-altering treatments like dialysis or kidney transplantation. Currently, these conditions can be difficult to diagnose early, and effective treatments are often limited or unknown. This bill matters because it seeks to accelerate scientific understanding and develop better ways to prevent, diagnose, and treat these diseases, potentially improving the quality of life and extending the lives of affected individuals.
If this bill becomes law, it could lead to earlier detection of rare kidney diseases through improved testing and greater public awareness, especially in communities where healthcare access is challenging. Better research could result in new treatments, slowing disease progression and reducing the number of people who develop end-stage kidney disease. Without this bill, research efforts might remain fragmented, public awareness could stay low, and progress in managing these rare conditions might continue at a slower pace, meaning more individuals would suffer the severe consequences of advanced kidney disease.
KEY PROVISIONS
4AI-extractedPROVISION 01
Establishes 'Centers of Excellence on Rare Kidney Disease Research' within the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
This creates dedicated, focused hubs for advanced research and clinical expertise on rare kidney diseases, ensuring sustained effort in this area.
PROVISION 02
Requires these Centers of Excellence to conduct research on the causes, diagnosis, progression, and treatment of rare kidney diseases and to increase public awareness.
This provision directs funding towards essential scientific investigation and public education, both critical for improving patient outcomes.
PROVISION 03
Mandates a study by the Secretary of Health and Human Services on testing, preventative care, precision medicine, and treatment for rare kidney disease, including an analysis of genetic testing and barriers to access.
This comprehensive review will identify current challenges and opportunities to improve early detection and treatment strategies across the healthcare system.
PROVISION 04
Prohibits the use of quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs) in research funded by the centers, specifically for populations studied in such research.
This ensures that research into treatments for rare kidney diseases does not discriminate against individuals with disabilities by devaluing their lives in cost-effectiveness assessments.
SPONSORSHIP
1 + 56
R· Florida
YRS IN OFFICE
19
BILLS LED
35
COSPONSOR BREAKDOWNBIPARTISAN · 50%
DEM 42 REP 14 IND 0
ACTION TIMELINE
2 EVENTSFEB 24
Introduced in House
FEB 24
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
BILL INFO
TypeHouse Bill
NumberHR 1518
Congress119th
StatusIn Committee
IntroducedFeb 24, 2025
Last actionFeb 24, 2025
READER REACTIONS
OVERALL SENTIMENT
No reactions yet. Be the first to weigh in.
Discussion
Loading comments...
IN COMMITTEE· 119TH CONGRESS · WAYS AND MEANS COMMITTEE · INTRODUCED FEB 24, 2025
House BillHR 1518Medical researchResearch administration and funding
New Era of Preventing End-Stage Kidney Disease Act
INTRODUCED FEB 24, 2025· LAST ACTION FEB 24, 2025
PASSAGE CHANCES
—%
READING
8 min
COSPONSORS
56
COMPLEXITY
Moderate
